This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
This observational study is a single-center, prospective cohort study, which aims to detect minimal residual disease (MRD) using circulating tumor cells (CTC) and circulating tumor DNA (ctDNA). To evaluate the effectiveness and superiority of MRD detection, we enroll operable or inoperable IIA-IIIC stage NSCLC patients, and single-cell RNA sequencing and genomic sequencing would be performed for CTC and ctDNA, respectively.
Study Type
OBSERVATIONAL
Enrollment
60
Enrolled patients capable of surgical treatment
Jiangsu Cancer Institute & Hospital
Nanjing, Jiangsu, China
RECRUITINGTo evaluate the Progression-free Survival (PFS)
Progression-free survival (PFS) is defined as the time from the start of treatment to the occurrence of tumor progression or death due to any cause based on RECIST 1.1 assessed by investigator review.
Time frame: From the first study dose date to the date of first documentation of disease progression or death (whichever occurred first), up to approximately 3 years
To evaluate the Overall Survival (OS)
Overall Survival (OS) was measured from the date of first dose of study drug until date of death from any cause. Participants who were lost to follow-up and the participants who were alive at the date of data cutoff was censored at the date the participant was last known alive, whichever came earlier.
Time frame: From the date of first dose of study drug until date of death from any cause (up to approximately 5 years )
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.